Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-848d4c4894-2pzkn Total loading time: 0 Render date: 2024-06-02T10:27:14.394Z Has data issue: false hasContentIssue false

28 - Bone pain

from SECTION IX - DIFFICULT PAIN PROBLEMS

Published online by Cambridge University Press:  06 July 2010

By
BADI EL OSTA  and
EDUARDO D. BRUERA
Edited by
Eduardo D. Bruera  and
Russell K. Portenoy
BADI EL OSTA
Affiliation:
The University of Texas M. D. Anderson Cancer Center
EDUARDO D. BRUERA
Affiliation:
The University of Texas M. D. Anderson Cancer Center
Eduardo D. Bruera
Affiliation:
University of Texas, Houston
Russell K. Portenoy
Affiliation:
Albert Einstein College of Medicine, New York
Get access

Summary

Introduction

The skeleton is one of the most common sites of tumor metastases. Metastatic cancer invades bone in 60%–84% cases. Up to 80% of all bone metastases are related to cancer of the breast, prostate, lung, thyroid, and kidney. Multiple myeloma also is commonly associated with skeletal disease. Approximately 70% of patients with bone metastases develop pain. In addition to pain, metastatic bone disease results in immobility, frequent hospital admissions, pathological fractures, metabolic complications such as hypercalcemia, neurological abnormalities, and bone marrow infiltration and suppression. These devastating symptoms may have a prolonged effect and also have major psychosocial implications. Detection of bone metastases may be the first indicator that cancer has not been cured; bone is the first site of recurrence in up to 40% of women with breast cancer. Patients suffering from bone metastases secondary to breast cancer survive an average of 34 months, with a range of 1–90 months.

This chapter primarily discusses pain associated with bone metastases. It also addresses some of the recent developments in the prevention and management of osteolysis.

Pathophysiology of bone pain

The invasion of bone by tumor is well understood; however, the mechanisms of nociception are not well known. The three main mechanisms by which the skeleton is affected by cancer are primary bone cancer, direct invasion from adjacent primary tumors, and bone metastases. The last is by far the most common mechanism; primary tumors of bone are much less frequent.

Type
Chapter
Information
Cancer Pain
Assessment and Management
 , pp. 515 - 532
Publisher: Cambridge University Press
Print publication year: 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Galasko, CSB. Skeletal metastases. Clin Orthoped 210:18–30, 1986.Google Scholar
Pereira, J. Management of bone pain. In: Portenoy, R, Bruera, E, eds. Topics in palliative care, vol. 3. New York, Oxford: Oxford University Press, 1998, pp 79–116.Google Scholar
Lote, K, Walloe, A, Bjersand, A. Bone metastases: prognosis diagnosis and treatment. Acta Radiol Oncol 25:227–32, 1986.CrossRefGoogle ScholarPubMed
Koenders, PG, Beex, LV, Kloppenborg, PWC, et al. Human breast cancer: survival from metastases. Breast Cancer Res Treat 21:173–80, 1992.CrossRefGoogle Scholar
Liotta, , Stetler-Stevenson, WGD. Principles and practice of oncology. Philadelphia: Lippincott, 1989, pp 98–115.Google Scholar
Nilsen, OS, Munro, AJ, Tannock, F. Bone metastases: pathophysiology and management policy. J Clin Oncol 25:227–32, 1986.Google Scholar
Berretoni, BA, Carter, JR. Mechanisms of cancer metastases to bone. J Bone Joint Surg 68A:308–12, 1986.CrossRefGoogle Scholar
Carter, RL. Patterns and mechanisms of bone metastases. J R Soc Med 78(Suppl 9):2–6, 1985.Google ScholarPubMed
Mundy, GR, Raisz, LG, Cooper, RA, et al. Evidence for the secretion of an osteoclast stimulating factor in myeloma. N Eng J Med 291:1041–6, 1974.CrossRefGoogle Scholar
Frassica, FJ, Frassica, DA, Lietman, SA, et al. Surgical palliation of malignant bone pain. In: Portenoy, R, Bruera, E, eds. Topics in palliative care, vol 3. New York, Oxford: Oxford University Press, 1998, pp 139–62.Google Scholar
Honore, P, Rogers, SD, Schwei, MJ, et al. Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons. Neuroscience 98:585–98, 2000.CrossRefGoogle ScholarPubMed
Luger, NM, Mach, DB, Sevcik, MA, Mantyh, PW. Bone cancer pain: from model to mechanism to therapy. J Pain Symptom Manage 29(5 Suppl):S32–S46, 2005.CrossRefGoogle Scholar
Jemal, A, Murray, T, Ward, E, et al. Cancer statistics, 2005. CA Cancer J Clin 55:10–30, 2005.CrossRefGoogle ScholarPubMed
Mach, DB, Rogers, SD, Sabino, MC, et al. Origins of skeletal pain: sensory and sympathetic innervation of the mouse femur. Neuroscience 113:155–66, 2002.CrossRefGoogle ScholarPubMed
Honore, P, Luger, NM, Sabino, MA, et al. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat Med 6:521–8, 2000.Google ScholarPubMed
Albright, JA, Gillespie, TE, Butaud, TR. Treatment of bone metastases. Semin Oncol 17:418–34, 1980.Google Scholar
Morton, AR, Ritch, PS. Hypercalcemia. In: Berger, AM, Portenoy, RK, Weissman, , eds. Principles and practice of supportive oncology. Philadelphia, New York: Lippincott, 1998, pp 411–25.Google Scholar
Healley, JH. Metastatic cancer to the bone. In DeVita, VT, Hellman, S, Rosenberg, SA, eds. Cancer principles and practice of oncology. Philadelphia, New York: Lippincott, 1997, pp 2570–86.Google Scholar
Koyama, H, Wada, T, Nishizawa, Y, et al. Cyclophosphamide induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer 39:1403–9, 1977.3.0.CO;2-8>CrossRefGoogle ScholarPubMed
Friedlender, GE, Tross, RB, Doganis, AC, et al. Effects of chemotherapeutic agents on bone. Short-term methotrexate and doxorubicin treatment in a rat model [abstract]. J Bone Joint Surg 66A:602–7, 1984.CrossRefGoogle Scholar
Kanis, JA, McCloskey, EV, Powles, T, et al. A high incidence of vertebral fracture in women with breast cancer. Br J Cancer 78:1179–81, 1999.CrossRefGoogle Scholar
Portenoy, RK, Hagen, N. Breakthrough pain. Definition, prevalence and characteristics. Pain 41:273–83, 1990.CrossRefGoogle ScholarPubMed
Coleman, RE. Skeletal complications of malignancy. Cancer 80(Suppl 8):1588–94, 1997.3.0.CO;2-G>CrossRefGoogle Scholar
Bruera, E, Macmillan, K, Hanson, J, Macdonald, RN. The Edmonton staging system for cancer pain: preliminary report. Pain 37:203–9, 1989.CrossRefGoogle ScholarPubMed
Cleeland, C, Portenoy, RK, Bruera, E, et al. Systematic approaches to cancer pain management [abstract]. Proc Am Pain Soc 81:130, 1991.Google Scholar
Hanks, GW, Justins, DM. Cancer pain: management. Lancet 339:1031–6, 1992.CrossRefGoogle ScholarPubMed
O'Neill, WM, Justins, DM, Hanks, GW. Pain associated with malignant disease. Curr Opin Anaesthesiol 6:845–51, 1993.CrossRefGoogle Scholar
Plunkett, TA, Smith, P, Rubens, RD. Risks of complications from bone metastases in breast cancer. Eur J Cancer 36:476–82, 2000.CrossRefGoogle ScholarPubMed
Hortobagyi, GN, Theriault, RL, Porter, L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 335:1785–91, 1996.CrossRefGoogle ScholarPubMed
Campa, JA, Payne, R. The management of intractable bone pain: a clinician's perspective. Semin Nucl Med 22:3–10, 1992.CrossRefGoogle ScholarPubMed
Hanks, GW. Pharmacological treatment of bone pain. Cancer Surv 7:87–101, 1998.Google Scholar
Pereira, J. The management of bone pain. In: Portenoy, RK, Bruera, E, eds. Topics in palliative care, vol. 3. New York: Oxford University Press, 1998, pp 79–116.Google Scholar
Pereira, J, Bruera, E. Emerging neuropsychiatric toxicities of opioids. J Pharm Care Pain Symptom Control 5:3–29, 1997.CrossRefGoogle Scholar
Payne, R. Mechanisms and management of bone pain. Cancer 80(8 Suppl):1608–13, 1997.3.0.CO;2-3>CrossRefGoogle ScholarPubMed
Bruera, E, Fainsinger, R, MacEachern, T, Hanson, J. The use of methylphenidate in patients with incident cancer pain receiving regular opiates. A preliminary report. Pain 50:75–7, 1992.CrossRefGoogle ScholarPubMed
Coluzzi, P. A titration study of oral transmucosal fentanyl citrate for breakthrough pain in cancer patients [abstract #143]. Proceedings of ASCO 16:41a, 1997.Google Scholar
Lyss, AP. Long-term use of oral transmucosal fentanyl citrate (OTFC) for breakthrough pain in cancer patients [abstract #144]. Proceedings of ASCO 16:41a, 1997.Google Scholar
Foley, K. The treatment of cancer pain. N Engl J Med 313:84–95, 1985.CrossRefGoogle ScholarPubMed
Eisenberg, E, Berkey, CS, Carr, DB, et al. Efficacy and safety of nonsteroidal anti-inflammatory drugs for cancer pain: a meta-analysis. J Clin Oncol 12:2756–65, 1994.CrossRefGoogle ScholarPubMed
Stiefel, F, Morant, R. Case report: morphine intoxication during acute reversible renal insufficiency. J Palliat Care 7:45–7, 1991.Google ScholarPubMed
Fainsinger, RL, Miller, MJ, Bruera, E. Letter to the editor re: morphine intoxication during acute reversible renal insufficiency. J Palliat Care 8:52–3, 1992.Google Scholar
Masferrer, J, Zweifel, B, Manning, PT, et al. Selective inhibition of inducible cyclooxygenase 2 in vivo is anti-inflammatory and non-ulcerogenic. Proc Natl Acad Sci U S A 91:3228–32, 1994.CrossRefGoogle Scholar
Ettinger, AB, Portenoy, RK. The use of corticosteroids in the treatment of symptoms associated with cancer. J Pain Symptom Manage 3:99–103, 1988.CrossRefGoogle ScholarPubMed
Levy, M. Pharmacological treatment of cancer pain. N Engl J Med 335:1124–32, 1996.CrossRefGoogle ScholarPubMed
Grant, R, Papadopoulos, SM, Sandler, HM, Greenberg, HS. Metastatic epidural spinal cord compression: current concepts and treatment. J Nuclear Oncol 19:79–92, 1994.Google ScholarPubMed
Twycross, R. The risks and benefits of corticosteroids in advanced cancer. Drug Saf 11:163–78, 1994.CrossRefGoogle ScholarPubMed
Stiefel, FC, Breitbard, WS, Holland, JC. Corticosteroids in cancer: neuropsychiatric complications. Cancer Invest 7:479–91, 1989.CrossRefGoogle ScholarPubMed
Vincent, FM. The neuropsychiatric complications of corticosteroid therapy. Compr Ther 21:524–8, 1995.Google ScholarPubMed
Dropcho, EJ, Twycross, RG, Trueman, T. Steroid-induced weakness in patients with primary brain tumors. Postgrad Med J 59:702–6, 1983.Google Scholar
Fulfaro, F, Casuccio, A, Ticozzi, C, et al. The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials. Pain 78:157–69, 1998.CrossRefGoogle ScholarPubMed
Body, JJ. Bisphosphonates for metastatic bone pain. Support Care Cancer 7:1–3, 1999.CrossRefGoogle ScholarPubMed
Lucas, LK, Lipman, AG. Recent advances in pharmacotherapy for cancer pain management. Cancer Pract 10(Suppl 1):14S–20S, 2002.CrossRefGoogle ScholarPubMed
Pavlakis, N, Stockler, M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev CD003474, 2002.CrossRefGoogle Scholar
Ernst, DS, MacDonald, RN, Paterson, AHG, et al. A double-blind, crossover trial of intravenous clodronate in metastatic bone pain. J Pain Symptom Manage 7:4–11, 1992.CrossRefGoogle ScholarPubMed
Hortobagyi, GN, Theriault, RL, Lipton, A, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate: Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 16:2038–44, 1998.CrossRefGoogle Scholar
Boissier, S, Ferreras, M, Peyruchaud, O, et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 60:2949–54, 2000.Google ScholarPubMed
Diel, IJ. Antitumor effects of bisphosphonates: first evidence and possible mechanisms. Drugs 59:391–9, 2000.CrossRefGoogle Scholar
Boissier, S, Magnetto, S, Frappart, L, et al. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 57:3890–4, 1997.Google ScholarPubMed
Fulfaro, F, Casuccio, A, Ticozzi, C, Ripamonti, C. The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials. Pain 78:157–69, 1998.CrossRefGoogle ScholarPubMed
Walker, P, Watanabe, S, Lawlor, P, et al. Subcutaneous clodronate: a study evaluating efficacy in hypercalcemia of malignancy and local toxicity. Ann Oncol 8:915–16, 1997.CrossRefGoogle ScholarPubMed
Walker, P, Bruera, E. The role of bisphosphonates in the prevention of osteolysis in palliative care patients. 12th International Congress on Care of the Terminally Ill. J Palliat Care 14:120, 1998.Google Scholar
Bloomfield, DJ. Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review. J Clin Oncol 16:1218–25, 1998.CrossRefGoogle ScholarPubMed
Lipton, A, Theriault, RL, Hortobagyi, GN, et al. Pamidronate prevents skeletal complications and is effective palliating treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 88:1082–90, 2000.3.0.CO;2-Z>CrossRefGoogle ScholarPubMed
Patterson, AH, Powles, TJ, Kanis, JA, et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 11:59–65, 1993.CrossRefGoogle Scholar
Kristensen, B, Ejlertsen, B, Groenvold, M, et al. Oral clodronate in breast cancer patients with bone metastases: a randomized study. J Intern Med 246:67–74, 1999.CrossRefGoogle ScholarPubMed
Kanis, JA, Powles, T, Patterson, AH, et al. Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone 19:663–7, 1996.CrossRefGoogle ScholarPubMed
Diel, IJ, Solomayer, EF, Costa, SD, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 339:357–63, 1998.CrossRefGoogle ScholarPubMed
Diel, IJ, Solomayer, E, Gollan, C, et al. Bisphosphonates in the reduction of metastases in breast cancer – results of the extended follow-up of the first study population [abstract]. Proc Am Soc Clin Oncol 19:82, 2000.Google Scholar
Powles, TJ, Pattison, AH, Nevantaus, A, et al. Adjuvant clodronate reduces the incidence of bone metastases in patients with primary operable breast cancer [abstract]. Proc Am Soc Clin Oncol 17:468, 1998.Google Scholar
Saarto, T, Blomqvist, C, Virkkunen, P, et al. No reduction of bone metastases with adjuvant clodronate treatment in node positive breast cancer patients [abstract]. Proc Am Soc Clin Oncol 18:489, 1999.Google Scholar
McIntyre, E, Bruera, E. Case report. Symptomatic hypocalcemia after intravenous pamidronate. J Palliat Care 12:46–7, 1996.Google ScholarPubMed
Purohit, OP, Anthony, C, Radstone, CR, et al. High-dose intravenous pamidronate for metastatic bone pain. Br J Cancer 70:554–8, 1994.CrossRefGoogle ScholarPubMed
Gatti, D, Adami, S. New bisphosphonates in the treatment of bone diseases. Drugs Aging 15:285–96, 1999.CrossRefGoogle ScholarPubMed
Major, P, Lortholary, A, Hon, J, et al. Zoledronic acid is superior to pamidronate in the treatment of tumor-induced hypercalcemia: a pooled analysis [abstract]. Proc Am Soc Clin Oncol 19:604, 2000.Google Scholar
Mortensen, L, Charles, P, Bekker, PJ, et al. Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow up. J Clin Endocrinol Metab 83:396–402, 1998.Google Scholar
Delmas, PD, Balena, R, Confravreux, E. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind placebo controlled study. J Clin Oncol 15:955–62, 1997.CrossRefGoogle ScholarPubMed
Coleman, RE, Purohit, OP, Black, C, et al. Double-blind, randomized placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease. Ann Oncol 10:311–16, 1999.CrossRefGoogle ScholarPubMed
Rosen, LS, Gordon, D, Kaminski, M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 7:377–87, 2001.Google ScholarPubMed
Mancini, I, Dumon, JC, Body, JJ. Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study. J Clin Oncol 22:3587–92, 2004.CrossRefGoogle ScholarPubMed
Major, PP, Lipton, A, Berenson, J, Hortobagyi, G. Oral bisphosphonates a review of clinical use in patients with bone metastases. Cancer 88:6–14, 2000.3.0.CO;2-D>CrossRefGoogle ScholarPubMed
Hillner, BE, Ingle, JN, Berenson, JR, et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. J Clin Oncol 18:1378–91, 2000.CrossRefGoogle Scholar
Devogelaer, JP. Clinical use of bisphosphonates. Curr Opin Rheumatol 8:384–91, 1996.CrossRefGoogle ScholarPubMed
Wyngaert, T, Huizing, MT, Vermorken, JB. Bisphosphonates and osteonecrosis of the jaw: cause and effect or a post hoc fallacy?Ann Oncol 17:1197–204, 2006.CrossRefGoogle ScholarPubMed
Bamias, A, Kastritis, E, Bamia, C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23:8580–7, 2005.CrossRefGoogle ScholarPubMed
Kademani, D, Kako, S, Lacy, MQ, Rajkumar, SV. Primary surgical therapy for osteonecrosis of the jaw secondary to bisphosphonate therapy. Mayo Clin Proc 81:1100–3, 2006.CrossRefGoogle ScholarPubMed
Schiraldi, GF, Soresi, E, Locicero, S, et al. Salmon calcitonin in cancer pain: comparison between two different treatment schedules. Int J Clin Pharmacol Ther Toxicol 25:229–32, 1987.Google ScholarPubMed
Quadt, C, Geyer, J, Weiner, N, et al. Effects of salmon calcitonin on bone metastases in breast cancer patients. Eur J Pharmacol 183:1702, 1990.CrossRefGoogle Scholar
Mystakidou, K, Befon, S, Hondros, K. Continuous subcutaneous administration of high-dose salmon calcitonin in bone metastasis: pain control and beta-endorphin plasma levels. J Pain Symptom Manage 18:323–30, 1999.CrossRefGoogle ScholarPubMed
Kreeger, L, Hutton-Potts, J. The use of calcitonin in the treatment of metastatic bone pain. J Pain Symptom Manage 17:2–5, 1999.Google ScholarPubMed
Hoskin, PJ. Radiotherapy for bone pain. Pain 63:137–9, 1995.CrossRefGoogle ScholarPubMed
Salazar, OM, Rubin, P, Hendrickson, FR, et al. Single-dose half-body irradiation for palliation of multiple bone metastases from solid tumors. Final Radiation Therapy Oncology Group report. Cancer 58:29–36, 1986.3.0.CO;2-2>CrossRefGoogle ScholarPubMed
Macklis, RM, Cornelli, H, Lasher, J. Brief courses of palliative radiotherapy for metastatic bone pain: a pilot cost-minimization comparison with narcotic analgesics. Am J Clin Oncol 21:617–22, 1998.CrossRefGoogle ScholarPubMed
,Bone Pain Trial Working Party. 8 Gy single fraction radiotherapy for the treatment of metastatic skeletal pain: randomised comparison with a multifraction schedule over 12 months of patient follow-up. Radiother Oncol 52:111–21, 1999.CrossRefGoogle Scholar
Steenland, E, Leer, JW, Houwelingen, H, et al. The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch Bone Metastasis Study. Radiother Oncol 52:101–9, 1999.CrossRefGoogle ScholarPubMed
McQuay, HJ, Carroll, D, Moore, RA. Radiotherapy for painful bone metastases: a systematic review. Clin Oncol 9:150–4, 1997.CrossRefGoogle ScholarPubMed
Arcangeli, G, Giovinazzo, G, Saracino, B, et al. Radiation therapy in the management of symptomatic bone metastases: the effect of total dose and histology on pain relief and response duration. Int J Radiat Oncol Biol Phys 42:1119–26, 1998.CrossRefGoogle ScholarPubMed
Lewington, VJ, McEwan, AJB, Ackery, DM, et al. A prospective, randomized double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer 27:954–8, 1991.CrossRefGoogle ScholarPubMed
Quilty, PM, Kirk, D, Bolger, JJ, et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 31:33–40, 1994.CrossRefGoogle ScholarPubMed
Serafini, AN, Houston, SJ, Resche, I, et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol 16:1574–81, 1998.CrossRefGoogle ScholarPubMed
Tian, JH, Zhang, JM, Hou, QT, et al. Multicenter trial on the efficacy and toxicity of single-dose samarium-153-ethylene diamine tetramethylene phosphonate as a palliative treatment for painful skeletal metastases in China. Eur J Nucl Med 26:2–7, 1999.CrossRefGoogle Scholar
Sciuto, R, Tofani, A, Festa, A, et al. Short- and long-term effects of 186Re-1,1-hydroxyethylidene diphosphonate in the treatment of painful bone metastases. J Nucl Med 41:647–54, 2000.Google Scholar
McEwan, AJB. Use of radionuclides for the palliation of bone metastases. Semin Radiat Oncol 10:103–14, 2000.CrossRefGoogle ScholarPubMed
Harrington, KD. Orthopedic surgical management of skeletal complications of malignancy. Cancer 80(8 Suppl):1614–27, 1997.3.0.CO;2-2>CrossRefGoogle Scholar
Fidler, M. Prophylactic internal fixation of secondary neoplastic deposits in long bones. Br Med J 1:341–3, 1973.CrossRefGoogle ScholarPubMed
Harrington, KD. Anterior decompression and stabilization of the spine as a treatment for vertebral collapse and spinal cord compression from metastatic malignancy. Clin Orthop Relat Res August:177–97, 1988.Google ScholarPubMed
Barr, JD, Barr, MS, Lemley, TJ, McCann, RM. Percutaneous vertebroplasty for pain relief and spinal stabilization. Spine 25:923–8, 2000.CrossRefGoogle ScholarPubMed
Wallson, KA, Burger, C, Smith, RA, Baugher, RJ. Comparing the quality of death for hospice and non-hospice cancer patients. Med Care 26:177–82, 1988.CrossRefGoogle Scholar
Burton, AW, Mendel, E. Vertebroplasty and kyphoplasty. Pain Physician 6:335–41, 2003.Google ScholarPubMed
Galibert, P, Deramond, H, Rosat, P, Le Gars, D. Preliminary note on the treatment of vertebral angioma be percutaneous acrylic vertebroplasty. Neurochirurgie 33:166–8, 1987.Google ScholarPubMed
Jensen, ME, Evans, AJ, Mathis, JM, et al. Percutaneous polymethylmethacrylate vertebroplasty in the treatment of osteoporotic vertebral body compression fractures: technical aspects. AJNR Am J Neuroradiol 18:1897–904, 1997.Google ScholarPubMed
Debussche-Depriester, C, Deramond, H, Fardellone, P, et al. Percutaneous vertebroplasty with acrylic cement in the treatment of osteoporotic vertebral crush fracture syndrome. Neuroradiology 1991; 33(suppl):149–52.Google Scholar
Kaemmerlen, P, Thiesse, P, Jonas, P, et al. Percutaneous injection of orthopedic cement in metastatic vertebral lesions. N Engl J Med 321:121, 1989.Google ScholarPubMed
Watts, NB, Harris, ST, Genant, HK. Treatment of painful osteoporotic vertebral compression fractures with percutaneous vertebroplasty or kyphoplasty. Osteoporosis Int 12:429–37, 2001.CrossRefGoogle ScholarPubMed
Garfin, SR, Yuan, HA, Reiley, MA. New technologies in spine: kyphoplasty and vertebroplasty for the treatment of painful osteoporotic compression fractures. Spine 26:1511–5, 2001.CrossRefGoogle ScholarPubMed
Birkmeyer, N. Point of view. Spine 26:1637–8, 2001.CrossRefGoogle Scholar
Fourney, DR, Schomer, DF, Nader, R, et al. Percutaneous vertebroplasty and kyphoplasty for painful vertebral body fractures in cancer patients. J Neurosurgery 98:21–30, 2003.Google ScholarPubMed
Wang, M, Weber, D, Fourney, D, et al. Value of vertebroplasty and kyphoplasty for painful vertebral compression fractures in multiple myeloma. Blood 11:403a, 2002.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Bone pain
  • Edited by Eduardo D. Bruera, University of Texas, Houston, Russell K. Portenoy, Albert Einstein College of Medicine, New York
  • Book: Cancer Pain
  • Online publication: 06 July 2010
  • Chapter DOI: https://doi.org/10.1017/CBO9780511642357.029
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Bone pain
  • Edited by Eduardo D. Bruera, University of Texas, Houston, Russell K. Portenoy, Albert Einstein College of Medicine, New York
  • Book: Cancer Pain
  • Online publication: 06 July 2010
  • Chapter DOI: https://doi.org/10.1017/CBO9780511642357.029
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Bone pain
  • Edited by Eduardo D. Bruera, University of Texas, Houston, Russell K. Portenoy, Albert Einstein College of Medicine, New York
  • Book: Cancer Pain
  • Online publication: 06 July 2010
  • Chapter DOI: https://doi.org/10.1017/CBO9780511642357.029
Available formats
×